SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can engineered immune cells tame stubborn autoimmune diseases?
Disease control Not yet recruitingThis phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
Disease control Not yet recruitingThis early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Immune cells engineered to fight lupus enter first human tests
Disease control Not yet recruitingThis early-stage trial tests a new treatment called KN5501 for people with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) to target and destroy faulty B cells that drive the disease. Partic…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Ruitherapeutics Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
A simple blood marker may reveal hidden heart risks in lupus
Knowledge-focused Not yet recruitingThis study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC